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Abstract
Burkholderia cepacia complex (Bcc) bacteria have gained notoriety as pathogens in cystic ﬁbrosis (CF) because they are difﬁcult to
identify and treat, and also have the ability to spread between CF individuals. Of the 17 formally named species within the complex,
Burkholderia multivorans and Burkholderia cenocepacia dominate in CF. Multilocus sequence typing has proven to be a very useful tool for
tracing the global epidemiology of Bcc bacteria and has shown that B. cenocepacia strains with high transmissibility, such as the ET-12
strain (ST-28) and the Czech strain (ST-32), have spread epidemically within CF populations in Canada and Europe. The majority of
research on the molecular pathogenesis of Bcc bacteria has focused on the B. cenocepacia ET-12 epidemic lineage, with gene mutation,
genome sequence analysis and, most recently, global gene expression studies shedding considerable light on the virulence and antimicro-
bial resistance of this pathogen. These studies demonstrate that the ability of B. cenocepacia to acquire foreign DNA (genomic islands,
insertion sequences and other mobile elements), regulate gene expression via quorum sensing, compete for iron during infection, and
mediate antimicrobial resistance and inﬂammation via its membrane and surface polysaccharides are key features that underpin the
virulence of different strains. With the wealth of molecular knowledge acquired in the last decade on B. cenocepacia strains, we are now
in a much better position to develop strategies for the treatment of pathogenic colonization with Bcc and to answer key questions on
pathogenesis concerning, for example, the factors that trigger the rapid clinical decline in CF patients.
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Introduction
Recurrent or chronic respiratory infection is one of the
major factors that negatively affect the length of life in indi-
viduals with cystic ﬁbrosis (CF). Infections result in a decline
of pulmonary function and therapeutic options that can mini-
mize their impact on patient health are still very limited. An
unfavourable course of pulmonary disease and progression of
a lung tissue damage is an inherent consequence of CF path-
ophysiology [1], yet infectious agents such as bacteria also
play a major role in the process. They possess a multitude
of virulence factors, which they can activate or suppress at
different stages of infection, leading to both inﬂammation and
damage of the lung.
Patients with CF are vulnerable throughout their lives to
various bacterial infections that are caused in most instances
by opportunistic pathogens. One of the most threatening
pathogens in CF is Burkholderia cenocepacia, a member of a
bacterial group collectively referred to as the Burkholderia
cepacia complex (Bcc). The complex currently consists of 17
genetically closely related bacterial species [2–4] that may be
isolated from sites of human infection as well as the natural
environment [5]. Several Bcc species have been shown to be
transmissible from one CF patient to another and are able
to cause epidemic outbreaks [6]; however, it is B. cenocepacia
and Burkholderia multivorans that predominate in CF, and
these are found in a signiﬁcantly higher percentage of respi-
ratory specimens. These two species together account for
approximately 85–97% of all Bcc infections in CF (the species
distribution in selected CF populations is summarized in
Table 1).
Although CF infection with any Bcc species may be
associated with poor prognosis, B. cenocepacia is consid-
ered one of the most serious pathogens because it is fre-
quently associated with reduced survival and highest risk
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of developing fatal cepacia syndrome [2,7]. B. cenocepacia
also contains the majority of epidemic strains described
so far [8–12]. In light of this, research on the pathogenic-
ity of Bcc bacteria has largely focused on B. cenocepacia,
with the ﬁrst sequenced Bcc genome being B. cenocepacia
strain J2315 [13,14]. Herein, we provide an overview
of the current knowledge on the epidemiology and
virulence mechanisms of Bcc, with a primary focus on
B. cenocepacia.
Epidemiology of B. cenocepacia: then and
now
Epidemiological studies from the late 1990s demonstrated
that B. cenocepacia (formerly Bcc genomovar III) was the
most prevalent Bcc pathogen in most CF populations stud-
ied worldwide [15,16]. By using a recA gene sequence anal-
ysis [17], the species was subdivided into four
phylogenetic clusters, IIIA to IIID, but almost all clinically
relevant isolates resided in the IIIA and IIIB groups. One
of the most notorious epidemic B. cenocepacia lineages is
known as ET-12, comprising a group of strains that have
been causing devastating infections in Canadian, UK and
European CF populations [2] subsequent to the ﬁrst
descriptions of the virulence of ‘Pseudomonas cepacia’ in
CF [18]. The ET-12 and several other epidemic strains
dominant in Canada [known as random ampliﬁed polymor-
phic DNA (RAPD) types 01, 04 and 06] [12] and Europe
(e.g. the CZ1 Czech epidemic clone) [9,19] all belong to
the B. cenocepacia IIIA subgroup [17,20]. By contrast, the
dominant B. cenocepacia epidemic clones in the USA are
part of the subgroup IIIB and include the Midwest clone
[8] and PHDC strain [10], which has also been found in
European CF patients [21].
In the last 5 years, the high prevalence of B. cenocepacia in
CF has remained in certain populations, such as in Czech
and Italian populations [9,22]. However, other countries have
reported an increase in the proportion of B. multivorans caus-
ing Bcc infections in CF [23,24], with B. cenocepacia ranking
second in dominance. This phenomenon may have resulted
from a combination of several factors such as: (i) application
of stringent infection control measures that prevented a
spread of epidemic strains (belonging mostly to B. cenocepa-
cia) [25] but were ineffective against acquisition of other Bcc
species living in the natural environment and (ii) the high
mortality rate within the group of patients who were
infected with B. cenocepacia that has reduced their numbers.
For example, at the Manchester adult CF centre [7], it was
observed that only 66.6% of their patients survived 5 years
after acquisition of B. cenocepacia. This 5-year survival rate
was signiﬁcantly lower compared to the rate calculated for
patients infected with Pseudomonas aeruginosa (5-year sur-
vival = 85.3%).
However, it is worth noting that not all CF populations
struggling with B. cenocepacia infection demonstrate such
poor survival. Data from the Prague adult CF centre indicate
that 91.4% of B. cenocepacia-positive patients reached a
5-year survival (L. Fila, Prague CF Centre, personal commu-
nication). Why the mortality rate differs among Bcc-infected
populations is not known; however it is tempting to specu-
late that B. cenocepacia strain differences are responsible for
the divergent clinical courses seen at these two CF centres.
Strains of the ET-12 lineage accounted for the B. cenocepacia
outbreak in the Manchester unit [7], whereas the Prague
patients were infected with strain CZ1 [9]. Although both
strains are very closely related as members of the B. ceno-
cepacia IIIA subgroup, the differences in survival rates
suggest that the strains have distinct virulence traits during
infection.
TABLE 1. Distribution of individual Burkholderia cepacia complex species in selected populations of cystic ﬁbrosis patients
Bcc species
USA [64]
(1218 patients;
1997 –2004)a
Canada [12]
(445 patients;
1994–2000)a
France [65]
(153 patients;
1995–2000)a
Czech Rep. [66]
(61 patients; 2001)a
Italy [67]
(53 patients;
1985–1999)a
Portugal [68]
(22 patients;
1995–2002)a
Burkholderia cepacia 3.1 0.2 0.0 0.0 2.9 36.4
Burkholderia multivorans 38.7 9.3 51.6 4.9 0.0 9.0
Burkholderia cenocepacia 45.6 80.0 45.1 91.8 86.8 52.2
Burkholderia stabilis 0.3 3.8 1.3 1.6 7.4 18.2
Burkholderia vietnamiensis 5.9 1.6 0.6 0.0 0.0 0.0
Burkholderia dolosa 3.8 0.0 0.0 0.0 0.0 0.0
Burkholderia ambifaria 0.8 0.0 0.0 0.0 0.0 0.0
Burkholderia anthina 0.2 –b 0.0 –b 0.0 0.0
Burkholderia pyrrocinia 0.3 –b 1.3 –b 2.9 0.0
Indeterminate 1.3 1.8 0.0 1.6 0.0 0.0
aThe number of patients examined and the period of study.
bThe species was not analyzed in the present study.
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Contribution of multilocus sequence typing (MLST) to
epidemiology
A new insight into the global epidemiology of B. cenocepacia
has been offered by MLST, a recently developed typing tech-
nique [26] based on the comparison of nucleotide sequences
of seven housekeeping genes. Individual strains are character-
ized by a sequence type (ST), an arbitrary number that rep-
resents a unique combination of seven sequenced alleles.
MLST analysis of the Bcc has led to the revision of the
extent of genetic relatedness among and within individual
epidemic lineages. Although some clones deﬁned previously
by typing methods, such as the RAPD assay, remained single
STs (e.g. all RAPD group 06 isolates originally described in
Canada [27] are ST-210), other B. cenocepacia epidemic
clones have turned out to encompass several different STs.
Another remarkable ﬁnding derived from MLST analysis is
that isolates of the ET-12 lineage appear to belong to at least
ﬁve different STs, with only ST-28 representing the ET-12
clone responsible for intercontinental spread between Can-
ada and the UK (A. Baldwin, personal communication;
Fig. 1).
New globally-distributed epidemic strain revealed
ET-12 (ST-28) was recognized as a globally spread B. ceno-
cepacia epidemic strain prior to the application of MLST;
however, the existence of other globally-distributed strains
was conﬁrmed using this powerful typing tool. Recently, it
was shown that a Canadian epidemic strain type, RAPD 01
[27], and the Czech epidemic strain, CZ1 [9], were both
sequence type ST-32, and that this ST is found in other
countries around the world [19] (Fig. 1). How the ST-32
strain spread to multiple countries has not yet been
elucidated. Intercontinental spread of the ET-12 strain has
been linked to social contact at summer camps organized
for CF patients [28]; however, no obvious epidemiological
link between the location and source of ST-32 isolates is
apparent.
We can speculate that ST-32 is either an inhabitant of a
common environmental niche to which CF patients are
exposed, or that it may have been spread as a result of con-
tamination of healthcare or domestic products commonly
used by individuals with CF. There is little epidemiological
evidence to support a speciﬁc natural source of ST-32
because the only environmental isolate of this ST was culti-
vated from a radish in Mexico [5]. Indeed, a fascinating
aspect of the ecology of B. cenocepacia IIIA strains is that
they have been rarely found outside of human infections in
comparison to other B. cenocepacia recA lineages and the Bcc
as a whole [5]. Bcc isolates linked to industrial contamination
have been shown to consist of various Bcc species and
strains, but as yet not of ST-32 isolates (see MLST database
at: http://pubmlst.org/bcc; [5]). Evidence to support the abil-
ity of ST-32 isolates to contaminate healthcare settings and
to spread nosocomially has been recently provided by Grain-
dorge et al. [29]. Their study showed that ST-32 isolates had
caused an outbreak of B. cenocepacia infection among seven
mechanically ventilated patients in a French intensive care
unit, demonstrating the high transmissibility of this strain in
outbreak scenarios outside of CF.
Although ST-28 and ST-32 are close relatives within the
B. cenocepacia IIIA lineage, they differ from each other by
polymorphisms in three MLST alleles. From a clinical point of
ST-32
ST-28
ST-32
ST-32
ST-32
ST-234
ST-220
ST-363
ST-32
ST-201
ST-309ST-218
ST-280
ST-359
ST-234
ST-364
ST-28   ST-227 ST- 248
ST-32   ST-234  ST-250
ST-208 ST-241  ST-256
ST-28   ST-33     
ST-29  ST-209   ST-264
ST-30  ST-210   ST-276
ST-31  ST-234   ST-278
ST-32  ST-241  ST-306
FIG. 1. Global distribution of Burkholde-
ria cenocepacia IIIA strains that were
analyzed by multilocus sequence typing
(MLST) and deposited in the public
MLST database.
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view, ST-28 and ST-32 also differ in terms of the progression
of the infections they cause, as well as with respect to 5-year
survival, as mentioned above. The differences apparent in the
virulence of each strain suggest they may have different
responses to the conditions of chronic lung infection. We
conducted a study that, for the ﬁrst time, compared the
behaviour of both epidemic strains under conditions of oxi-
dative stress, an attribute of chronically inﬂamed CF lungs
[19]. The exposure to reactive oxygen species had a consid-
erable effect on genomic rearrangements in ST-32, as
observed by pulsed-ﬁeld gel electrophoresis, and it also
enhanced the transposition activity of the mobile element
ISBcen20. By contrast, no changes were detected under the
same stress conditions for ST-28. The results suggested that
movement of mobile elements was strain-speciﬁc and the
degree of genomic stability may differ substantially even
between closely-related B. cenocepacia strains. The pheno-
typic impact of such rapid IS-mediated changes in the gen-
ome of B. cenocepacia remains to be studied, but may lead,
for example, to the reduced virulence of ST-32 compared to
ST-28.
Although many B. cenocepacia IIIA strains have been impli-
cated in outbreaks of infection among CF patients [12,27],
ST-28 and ST-32 strains are the only strains characterized by
MLST that are present in multiple globally-distinct locations,
and which, taken together, appear to account for a very
large proportion of CF infections attributed to B. cenocepacia
IIIA.
Virulence Factors from a Genomic and
Transcriptomic Perspective
The most basic question as to why B. cenocepacia is able to
colonize speciﬁcally and almost exclusively the respiratory
tract of patients with CF remains unanswered. Although the
pathogen is known also to be associated with immunodeﬁ-
ciency in chronic granulomatous disease (CGD) [30], no
immune defect similar to CGD is present in CF.
A speciﬁc link between CF and infection has been postu-
lated only for P. aeruginosa which takes advantage of an
impaired epithelial cell protein that no longer functions as a
receptor for internalization and clearance of the bacteria
from the respiratory system [31]. Another equally important
question to be answered relates to understanding why
B. cenocepacia is an aggressive pathogen that, in many cases,
ultimately leads to a patient’s death.
Both issues are being addressed by intensive research
concerning the pathogenesis of the B. cenocepacia infection,
which includes: (i) the identiﬁcation of bacterial virulence fac-
tors and (ii) the study of pathogen–host cell interaction. A
recent review by McClean and Callaghan [32] summarized
the mechanisms of the Bcc interaction with respiratory epi-
thelium cells where virulence factors critical for bacterial
adherence, cell invasion, intracellular survival and epithelial
layer penetration are well described. Here, we provide an
overview of B. cenocepacia virulence factors with a speciﬁc
focus on the bacterial genome and transcriptome. The gen-
ome of B. cenocepacia IIIA strain J2315 belonging to ST-28
has been recently annotated [13] and its complete sequence
information has allowed the design of a whole-genome DNA
chip [33]. By using a microarray technology or cDNA
sequencing, several global gene expression studies of B. ceno-
cepacia that model environmental and infection-related inter-
actions have been made available [34–37].
Using a mutation-based approach, many B. cenocepacia
genes encoding putative virulence factors have also been suc-
cessfully inactivated to study their virulence function
(Table 2).
Genomic islands and mobile elements
The complete genome sequence analysis of B. cenocepacia
J2315 revealed that it contained a staggering number of
genomic islands occupying 9.3% of its 8.06 Mb chromosome
[13]. Interestingly, of the fourteen islands described in strain
J2315, none were found as conserved entities in the two
genomes available for B. cenocepacia IIIB strains of the PHDC
lineage (AU1054 and HI2424). Holden et al. [13] hypothe-
sized that genomic islands may play a key role in the adap-
tion of ST-28 to survival in the CF lung and contribute
signiﬁcantly to the overall pool of B. cenocepacia IIIA viru-
lence factors.
Genomic island 11 is the most studied region of horizon-
tally acquired DNA in B. cenocepacia and was originally desig-
nated as the B. cenocepacia island (cci) [38]. The cci encodes
the B. cepacia epidemic strain marker (BCESM), a marker of
epidemic strains characterized before the revision of species
taxonomy within the Bcc [39]. Using comparative genomics,
Holden et al. [13] revised the annotation of the cci, demon-
strating it comprised a larger (44.1 kb) pathogenicity island
located on chromosome 2 that contained a total of 43
coding sequences (BCAM 0233–BCAM 0281). Genes encod-
ing an amidase (amiI), a porin (opcI) and a quorum-sensing
system (cciI and cciR) that are part of genomic island 11 have
been knocked out in previous studies, with the resulting
mutants demonstrating attenuated virulence and inﬂamma-
tory potential [38,40].
The island also contains a copy of ISBcen14, one of 22 dif-
ferent IS elements that reside within the J2315 genome. We
recently demonstrated that ISBcen20 lacked transposition
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activity in strain J2315, whereas a homologous IS element in
the Czech ST-32 B. cenocepacia strain responded to oxidative
stress by causing genomic rearrangements. Whether any of
the other 21 IS elements in the J2315 genome are capable of
movement when the B. cenocepacia is stressed remains to be
determined. The copy of ISBcen14 in genomic island 11 inter-
rupts a cluster of fatty acid biosynthesis genes and it would
be interesting to examine whether the virulence of strain
J2315 is altered by this mutation in the cci pathogenicity
island.
TABLE 2. Selected Burkholderia cenocepacia virulence genes that were studied by gene mutation
Gene name
ID in annotated
J2315 genome Product encoded Mutated straina References
Quorum sensing
cepR2 BCAM 0188 Response regulator K56-2, H111 42
cciI BCAM 0239a N-acylhomoserine lactone synthase K56-2 38,40
cciR BCAM 0240 Response regulator K56-2 40
cepR BCAM 1868 Response regulator K56-2 40,41
H111 69
cepI BCAM 1870 N-acylhomoserine lactone synthase K56-2 40,41
H111 69
Iron uptake
orbS BCAL 1688 RNA polymerase sigma factor KLF1 70
orbI BCAL 1696 Ornibactin biosynthesis peptide synthase KLF1 70
orbJ BCAL 1697 Ornibactin biosynthesis synthase KLF1 70
pvdA BCAL 1699 L-ornithine 5-oxygenase K56-2 71
orbA BCAL 1700 Ornibactin receptor precursor K56-2 72
BCAM 1187 TonB-dependent siderophore receptor K56-2 73
fptA BCAM 2224 Ferric-pyochelin outer membrane receptor Pc715j 44
phuV (hmuV) BCAM 2630 Haemin ATP-binding protein K56-2 73
Lipopolysaccharide
Core
hldD BCAL 2944 ADP-L-glycero-D-manno-heptose-6-epimerase K56-2 46
hldA BCAL 2945 D-b-D-heptose 7-phosphate kinase K56-2 46
O antigen
wbiI BCAL 3119 Nucleotide sugar epimerase/dehydratase K56-2 47
wbiG BCAL 3121 Nucleotide sugar epimerase/dehydratase K56-2 47
wbiF BCAL 3122 Glycosyltransferase K56-2 47
wbcE (wbxE) BCAL 3125 Glycosyltransferase K56-2 46,49
rmlD BCAL 3132 dTDP-4-keto-L-rhamnose reductase K56-2 47
Exopolysaccharide
cpxA BCAL 3240 Capsule polysaccharide export ATP-binding protein K56-2 47
bceA BCAM 0854 Mannose-1-phosphate guanylyltransferase IST408 74
bceD BCAM 0857 Protein-tyrosine-phosphatase IST408 75
bceF BCAM 0859 Tyrosine-protein kinase IST408 75
Antimicrobial resistance
amrA, amrB BCAL 1674–BCAL 1676 RND family efﬂux transporter J2315 57
oprM, bpeA BCAL 2820–BCAL 2822 RND family efﬂux transporter J2315 57
BCAS 0591–BCAS 0593 RND family efﬂux transporter J2315 57
Flagella and cable pilus
ﬂiC BCAL 0114 Flagellin (type II) K56-2 76
ﬂiI BCAL 0522 Flagellum-speciﬁc ATP synthase J2315 58
ﬂiG BCAL 0524 Flagellar motor switch protein J2315 58
adhA BCAM 2143 Cable pilus-associated adhesin BC7 77
cblS BCAM 2758 Sensor histidine kinase BC7 77
cblA BCAM 2761 Giant cable pilus BC7 77,78
Other virulence factors
rpoE BCAL 0998, BCAL 2872 RNA polymerase sigma-E factor K56-2 61
mucD BCAL 1001, BCAL 2869 Serine protease K56-2 61
sodC BCAL 2643 Superoxide dismutase K56-2 79
BCAL 2828 Putative exported protein K56-2 63
htrA BCAL 2829 Serine protease K56-2 63
BCAL 2831 Response regulator K56-2 63
katB BCAL 3299 Peroxidase/catalase C5424 80
amiI BCAM 0265 Putative amidase K56-2 38
opcI BCAM 0267 Putative porin K56-2 38
atsR BCAM 0379 Sensor histidine kinase/response regulator K56-2 81
BCAM 0392 Putative acetyltransferase K56-2 73
scpB BCAM 0957 Pepstatin-insensitive carboxyl proteinase K56-2 73
mgtC BCAM 1867 Putative Mg2+ transport ATPase K56-2 62
47
katA BCAM 2107 Peroxidase/catalase C5424 80
BCAM 2160 Response regulator K56-2 63
BCAM 2631 Putative membrane protein K56-2 73
aidA BCAS 0293 Nematocidal protein H111 82
K56-2 73,83
zmpA BCAS 0409 Zinc metalloprotease K56-2 60
aSpecies and strains used for mutagenesis in these studies were as follows: B. cenocepacia BC7 (LMG 18826); B. cenocepacia K56-2 (LMG 18863); B. cenocepacia J2315 (LMG
16656); B. cenocepacia C5424 (LMG 18827); B. cenocepacia Pc715j; B. cenocepacia H111, B. cenocepacia KLF1 and Burkholderia cepacia IST408.
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Quorum sensing
Quorum sensing is a form of bacterial cell-to-cell communi-
cation that regulates the expression of multiple genes,
including virulence genes, and operates through two main
components, an N-acyl-homoserine lactone (AHL) synthase
and a regulator which is responsive to AHL. B. cenocepacia
always possesses the CepI synthase with a CepR regulator
[41]. Strains with genomic island 11 encode additional quo-
rum-sensing components (i.e. the CciI synthase and the CciR
regulator) [38,40]. Interestingly, a third regulator has been
identiﬁed recently (designated CepR2) [42], although this has
not been found to be associated with any adjacently
encoded AHL synthase. An arsenal of genes have been iden-
tiﬁed that are regulated by quorum sensing and include
those for siderophore synthesis, protease production, a type
III secretion system, motility and bioﬁlm formation [43].
Recently, a transcriptomic approach was applied to B. ceno-
cepacia strain K56-2 aiming to examine the global gene
responses mediated by both quorum-sensing systems [36].
The study demonstrated that expression of the majority of
genes controlled by quorum sensing were regulated by
CepR, the putatively ancestral regulator found in all Bcc bac-
teria. In addition, CepR functioned primarily as a positive
regulator activating genes, whereas CciR was an inhibitor of
gene expression. Nevertheless, interaction between CepIR
and CciIR was also detected with approximately 200 genes
co-regulated in a reciprocal way by both quorum-sensing
systems.
Iron uptake
Under conditions of iron depletion, B. cenocepacia produces
two main siderophores, ornibactin and pyochelin, acting to
scavenge free iron from surrounding environment. Ornibac-
tin has been reported as the biologically more important
siderophore, and is able to compensate for the function of
pyochelin [44]. It has also been postulated that pyochelin
production may be defective in certain isolates such as
B. cenocepacia J2315, which contains a frameshift mutation
in pchF, one of the genes required for pyochelin biosynthe-
sis [13]. Interestingly, when strain J2315 was incubated in a
CF sputum-containing growth medium, several pyochelin
synthesis genes (pchR and pchD) were found to be upregu-
lated, but not ornibactin [35]. These expression data sug-
gest that the pyochelin pathway may still be functional in
strain J2315. Because CF sputum is an iron-deﬁcient envi-
ronment, it was not surprising that this study [35] also
revealed signiﬁcant upregulation of other genes involved in
iron uptake and metabolism. These included a novel mem-
brane ferric reductase gene (BCAL 0270) and cyaY (BCAL
0273), which may encode possible iron donors for the
assembly of Fe-S intracellular storage molecules during
infection.
Surface polysaccharides
One of the major components of the outer surface of Burk-
holderia bacteria is lipopolysaccharide (LPS). In certain
B. cenocepacia strains, the expression of a capsular exopoly-
saccharide (EPS) that gives bacterial colonies mucoid appear-
ance may also be seen; EPS production plays an important
role in the chronicity of Bcc infections [45]. All the genes for
LPS production are located on chromosome 1 with three
main clusters for lipid A (BCAL 1929–BCAL 1935), core
(BCAL 2402–BCAL 2408) and O antigen (BCAL 3110–BCAL
3125) [13], and additional sugar modiﬁcation genes, hldD/hldA
(BCAL 2944/BCAL 2945) [46] and rmlD (BCAL 3132) [47],
which are also located on this replicon (Table 2). The O
antigen is not expressed in some B. cenocepacia strains, such
as J2315, where there is an interruption of the wbcE gene
(BCAL 3125) by ISBcen20 [48]. B. cenocepacia strain K56-2
possesses a complete O antigen biosynthesis gene cluster
and expresses the O antigen; inactivation of this pathway by
mutation leads to a phenotype that is attenuated during
infection [47,48]. These O antigen mutants were also found
to be internalized into macrophages at signiﬁcantly higher
rates than the parental strain; however, their intracellular
survival was not affected [49].
B. cenocepacia strain J2315 also appears unable to produce
any EPS even though several gene clusters implicated in EPS
biosynthesis were identiﬁed within its genome. Cepacian, the
most abundant EPS among Bcc species [50], is not expressed
in J2315 as a result of a frameshift mutation in bceB (BCAM
0856) encoding a putative glycosyltransferase [13,51].
Although Bcc strains producing cepacian are able to develop
persistent infections in animal models [52], the role of EPS in
virulence is similar to that of O antigen. Although expression
of EPS is strain-speciﬁc and, when expressed, it appears to
enhance the virulence of the producer isolate, the absence
of EPS does not rule out that a Bcc strain may still cause a
severe infection.
Antimicrobial resistance
B. cenocepacia is intrinsically resistant to polymyxins, amino-
glycosides and most b-lactams, and can develop in vivo resis-
tance to essentially all classes of antimicrobial drugs. It
utilizes mechanisms of enzymatic inactivation (b-lactamases,
aminoglycoside-inactivating enzymes, dihydrofolate reduc-
tase), alteration of drug targets, cell wall impermeability and
active efﬂux pumps [53]. The genome of B. cenocepacia J2315
contains coding sequences for all ﬁve major families of efﬂux
systems [13], with the resistance-nodulation-division family
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(RND) arguably representing the best characterized efﬂux
system.
Thirteen operons of RND efﬂux transporters were identi-
ﬁed in J2315 [54] and one of the operons originally desig-
nated as the ceo cluster (BCAM 2549–2552, BCAM 2554)
was demonstrated to confer resistance to chloramphenicol,
trimethoprim and ciproﬂoxacin [55]. During growth in CF
sputum [35], B. cenocepacia J2315 upregulated the expression
of two RND efﬂux systems (BCAL 1675 and BCAM 1947)
and downregulated expression of another RND system
(BCAL 1813). However, this transcriptomic study did not
demonstrate any alteration in the ceo RND system, suggest-
ing that it is either not expressed in sputum or that insufﬁ-
cient levels of its substrate antimicrobials were present in
the sputum samples examined to upregulate its expression.
The activation of the other two efﬂux pumps in sputum may
be linked to the presence of trace quantities of antibiotics
because all the CF patients studied were on long-term anti-
biotic treatment. Alternatively, expression may have also
been associated with the need of bacterial cells to acquire
iron during infection because RND efﬂux pumps have been
implicated in the transport of siderophores in P. aeruginosa
[56]. The link between iron uptake and innate antimicrobial
resistance is intriguing because it suggests that, by increasing
siderophore secretion via RND pumps and adapting to the
iron-starved conditions of the CF lung, B. cenocepacia simul-
taneously increases its level of antimicrobial resistance. Inter-
estingly, two B. cenocepacia RND pumps (BCAL 1674–BCAL
1676 and BCAL 2822–BCAL 2820) have also been recently
linked to secretion of the quorum-sensing signal AHL [57].
This observation indicates that the RND efﬂux systems in
B. cenocepacia may transport multiple molecules and play a
pivotal role in the virulence and antimicrobial resistance of
this pathogen.
Motility and adherence
The ﬂagellum is an important virulence factor that not only
makes bacteria motile, but also serves as an adhesin and
enables pathogens to invade host cells [58]. Genes for syn-
thesis and assembly of ﬂagella in B. cenocepacia J2315 are dis-
tributed within ﬁve clusters on chromosome 1, with two
additional genes found on chromosomes 2 and 3 [13].
Increased transcriptional activity of ﬂagellar genes was
detected in B. cenocepacia when the organism was incubated
in CF sputum [35]. This observation contrasts with the anal-
ysis of the transcription proﬁle of P. aeruginosa, which is
known to become non-motile during chronic CF lung infec-
tion. Retained motility in B. cenocepacia may account for the
pathogen’s ability to invade host cells and to cause life-
threatening septicaemia. Another recent transcriptomic study
demonstrated that regulation of ﬂagellar gene transcription
was also quorum sensing-dependent [36].
B. cenocepacia strains of ET-12 lineage also express speciﬁc
ﬁmbriae, the cable pili, which, in association with the 22-kDa
adhesin AdhA (BCAM 2143), have been shown to play an
essential role in the invasion of respiratory epithelium [59].
Recent transcriptomic studies demonstrated the decreased
transcription of the cable pilus gene cluster (BCAM 2756–
BCAM 2762) during rapid growth in CF sputum [35], sug-
gesting that the whole ﬁmbrial structure may not be an
adhesive component as important as initially thought. How-
ever, the global gene expression analysis did shed light on a
potentially new role for the cable pilus-associated adhesin
AdhA during infection because its expression was signiﬁ-
cantly increased during the growth of B. cenocepacia in spu-
tum [35].
Other virulence factors
Other classic pathogenicity factors described in B. cenocepa-
cia include exoproducts such as zinc metalloproteases
(ZmpA and ZmpB; BCAS 0409 and BCAM 2307, respec-
tively) [60] and phospholipases C (BCAL 0443, BCAL 1046,
BCAM 0408, BCAM 1969, BCAM 2429 and BCAM 2720)
[13]. More recently, several studies have started to focus on
the mechanisms that B. cenocepacia uses to adapt to the
stressful conditions present in the CF lung environment and
to investigate genes that are under the control of response
regulators involved in the coordination of gene expression.
Mutations in the genes encoding homologues of the alterna-
tive sigma factor RpoE (BCAL 0998 = rpoE2 and BCAL
2872 = rpoE1; the gene is duplicated in J2315 genome) and
in mgtC (BCAM 1867) are associated with the inability of
B. cenocepacia to survive in macrophages [61,62]. In addition,
RpoE was also found to be required for growth under condi-
tions of osmotic stress and heat shock. Similarly, the HtrA
protease (encoded by BCAL 2829) has been shown to be
essential for survival at elevated temperatures and in the
presence of high salt [63]. To resist the harmful effects of
oxidative stress, B. cenocepacia may utilize several antioxidant
enzymes, including superoxide dismutases (cytoplasmatic
SodB and periplasmatic SodC; encoded by BCAL 2757 and
BCAL 2643, respectively), catalases, catalase-peroxidases
(katA, BCAM 2107 and katB, BCAL 3299) and alkyl-hydro-
peroxidase (BCAM 1216–BCAM 1217).
Concluding Remarks
Despite recent changes in the prevalence of the Bcc species, it
is clear that B. cenocepacia remains one of the most dominant
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and problematic CF pathogens from a worldwide perspective.
Tracking by MLST of the global distribution of Bcc strains
has revealed that, in addition to the well-characterized
B. cenocepacia strains of the ET-12 lineage, other epidemic
strains such as ST-32, most recently linked to the Czech CF
population, are widely distributed in several other countries.
The majority of studies on the molecular pathogenesis of
B. cenocepacia have focused on strains that belong to the IIIA
lineage (Table 2), and we know little about virulence determi-
nants in IIIB isolates that dominate B. cenocepacia infection in
the USA [15].
Factors involved in the pathogenesis of B. cenocepacia IIIA
infection include surface polysaccharides, adhesins, ﬂagella,
siderophores, efﬂux pumps, quorum-sensing systems and
metalloproteases, among others. The physical position and
transcriptomic units of these virulence determinants have
been mapped on the genome of B. cenocepacia J2315. Overall,
it is clear that the number of virulence genes implicated in
infection (Table 2) is far from complete and is likely to expand
considerably with genomic analysis methods becoming avail-
able for several B. cenocepacia CF strains [14]. A thorough
description of B. cenocepacia virulence is an essential prerequi-
site for the development of the next generation of antimicro-
bial drugs needed to treat life-threatening infections with
multidrug-resistant strains. The progression of Bcc infection is
both host- and strain-dependent, with different strains of
B. cenocepacia potentially exploiting a variable armoury of vir-
ulence factors. Although our knowledge of the B. cenocepacia
IIIA strain ST-28 has expanded substantially, the future charac-
terization of other IIIA and of IIIB strains is vital to gain a bal-
anced understanding of the virulence of B. cenocepacia in CF.
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